Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
Shimazu Y, Kanda J, Onda Y, Fuchida SI, Ohta K, Shimura Y, Kosugi S, Yamamura R, Matsuda M, Hanamoto H, Adachi Y, Anzai N, Hotta M, Fukushima K, Yagi H, Yoshihara S, Tanaka Y, Takakuwa T, Tanaka H, Shibayama H, Uoshima N, Hosen N, Ito T, Shimazaki C, Matsumura I, Kuroda J, Takaori-Kondo A, Hino M. Shimazu Y, et al. Among authors: hanamoto h. Cancer Immunol Immunother. 2024 May 17;73(7):135. doi: 10.1007/s00262-024-03711-8. Cancer Immunol Immunother. 2024. PMID: 38758239 Free PMC article.
Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.
Taniguchi Y, Tanaka H, Luis EJ, Sakai K, Kumode T, Sano K, Serizawa K, Rai S, Morita Y, Hanamoto H, Tsubaki K, Nishio K, Matsumura I. Taniguchi Y, et al. Among authors: hanamoto h. Int J Hematol. 2017 Nov;106(5):691-703. doi: 10.1007/s12185-017-2302-5. Epub 2017 Aug 5. Int J Hematol. 2017. PMID: 28780601 Clinical Trial.
Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.
Morita Y, Maeda Y, Yamaguchi T, Urase F, Kawata S, Hanamoto H, Tsubaki K, Ishikawa J, Shibayama H, Matsumura I, Matsuda M. Morita Y, et al. Among authors: hanamoto h. Cancer Sci. 2018 Oct;109(10):3209-3215. doi: 10.1111/cas.13739. Epub 2018 Aug 26. Cancer Sci. 2018. PMID: 30007103 Free PMC article. Clinical Trial.
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida SI, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Takakuwa T, et al. Among authors: hanamoto h. Eur J Haematol. 2021 Apr;106(4):555-562. doi: 10.1111/ejh.13586. Epub 2021 Jan 31. Eur J Haematol. 2021. PMID: 33476404
Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial.
Rai S, Inoue H, Hanamoto H, Matsuda M, Maeda Y, Wada Y, Haeno T, Watatani Y, Kumode T, Hirase C, Espinoza JL, Morita Y, Tanaka H, Tatsumi Y, Matsumura I. Rai S, et al. Among authors: hanamoto h. Int J Hematol. 2021 Aug;114(2):205-216. doi: 10.1007/s12185-021-03148-0. Epub 2021 Apr 17. Int J Hematol. 2021. PMID: 33864623
Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation.
Hotta M, Satake A, Yoshimura H, Fujita S, Katayama Y, Ota S, Hanamoto H, Oyake T, Ito S, Okada M, Nakanishi T, Ito T, Ishii K, Nomura S. Hotta M, et al. Among authors: hanamoto h. Transplant Cell Ther. 2021 Aug;27(8):660.e1-660.e8. doi: 10.1016/j.jtct.2021.04.025. Epub 2021 May 12. Transplant Cell Ther. 2021. PMID: 33989832 Free article.
Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.
Rai S, Inoue H, Sakai K, Hanamoto H, Matsuda M, Maeda Y, Haeno T, Watatani Y, Kumode T, Serizawa K, Taniguchi Y, Hirase C, Espinoza JL, Morita Y, Tanaka H, Ashida T, Tatsumi Y, Nishio K, Matsumura I. Rai S, et al. Among authors: hanamoto h. Cancer Sci. 2022 Feb;113(2):660-673. doi: 10.1111/cas.15224. Epub 2021 Dec 5. Cancer Sci. 2022. PMID: 34837284 Free PMC article.
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis.
Onda Y, Kanda J, Kaneko H, Shimura Y, Fuchida SI, Nakaya A, Itou T, Yamamura R, Tanaka H, Shibayama H, Shimazu Y, Uchiyama H, Yoshihara S, Adachi Y, Matsuda M, Hanamoto H, Uoshima N, Kosugi S, Ohta K, Yagi H, Kanakura Y, Matsumura I, Hino M, Nomura S, Shimazaki C, Takaori-Kondo A, Kuroda J; Kansai Myeloma Forum. Onda Y, et al. Among authors: hanamoto h. Ther Adv Hematol. 2022 Jun 24;13:20406207221104584. doi: 10.1177/20406207221104584. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35785245 Free PMC article.
81 results